# FewerJobs export - 100 curated jobs
Generated: 2026-08-11T03:23:12.808Z
Source: https://fewerjobs.com

## Filters applied
- **q**: Revolution Medicines
- **quality_floor**: default
- **match_401k_strict**: true
- **parental_strict**: true
- **non_birth_strict**: true
- **pto_strict**: true
- **include_older**: false
- **apply_url_verified**: false
- **page**: 1
- **per_page**: 100
- **sort**: relevance

## Jobs
### Director, Medical Information - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $201K-$251K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695099003
- Excerpt: Director, Medical Information Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated and experienced professional to join our team as a Director of Medical Information. This role focuses on ensuring the delivery of timely, accurate, and evidence-based responses to healthcare professionals (HCPs), patients, and caregivers. As a key member of the Medical Affairs team, you will oversee the creation and management of medical information content, support compendia submissions, and provide Medical Information support at congresses. The ideal candidate is a skilled communicator with a strong scientific background and can manage projects in a dynamic environment. Key Responsibilities: - Lead oversight and performance management of the global Medical Information call center, ensuring all customer inquiries are handled accurately, compliantly and within established timelines. - Maintains and monitors KPIs, and quality metrics, driving continuous improvement to ensure high-quality, consistent inquiry handling. - Prepares and presents regular reports on medical information performance metrics and outcomes to

### Director, Medical Science Liaison, California - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-04-24
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7714055003
- Excerpt: Director, Medical Science Liaison, California Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases of product development.

### Scientist II, Drug Product - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $132K-$166K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695483003
- Excerpt: Scientist II, Drug Product Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking Scientist II to join the Drug Product team within Pharmaceutical Development & Manufacturing (PDM). This role will support the development of solid oral dosage forms for small molecule programs across the RVMD pipeline. The successful candidate will contribute to formulation and process development activities from early-stage through late-stage clinical/commercial development, working closely with cross-functional partners and CDMOs to ensure robust, scalable, and compliant drug product manufacturing processes. Key Responsibilities: - Contribute to drug product development activities for new chemical entities (NCEs) from early development through late-stage clinical development, with exposure to commercialization activities. - Design and execute drug product development and manufacturing activities for solid oral dosage forms, including: - Preformulation and formulation development. - Manufacturing process development. - Process scale-up, technology transfer, and process optimization. - Process validation and commercial manufacturing support. - Support outsourced development and GMP

### Associate Director, Medical Lead GI, Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-06-09
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7767663003
- Excerpt: Associate Director, Medical Lead GI, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Medical Lead (ML) for Gastrointestinal and Pancreatic cancers (GI). This role will include to develop and execute strategic medical plan including evidence generation, publication, congress activities, and so on, engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and organize medical education, advisory boards, and medical activities in congresses. Reporting to the Head of Japan Medical Affairs, ML is an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. ML will serve as a key strategic person between Revolution Medicines and healthcare professionals in collaboration with MSL team. Within assigned geographic territory, ML will be

### Associate Director, Qualified Person, Europe - Revolution Medicines
- Location: Remote (Netherlands) (remote)
- Salary: Not disclosed
- Posted: 2026-05-01
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7648529003
- Excerpt: Associate Director, Qualified Person, Europe Remote (Netherlands) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Qualified Person (QP) holds ultimate responsibility for the certification and release of medicinal products in accordance with EU GMP, Directive 2001/83/EC, Dutch pharmaceutical legislation, and applicable Marketing Authorisations. The role provides independent, authoritative quality leadership across site operations and serves as a key member of the site leadership team, ensuring patient safety, product quality, regulatory compliance, and reliable supply. In addition to batch release accountability, the QP provides strategic oversight of the Pharmaceutical Quality System, partners closely with senior stakeholders across Quality, Technical Operations, Supply Chain, and Regulatory Affairs, and represents the site in interactions with Health Authorities. - Regulatory Accountability & Product Release - Act as the legally registered Qualified Person with full authority for certification and release of clinical and commercial medicinal products. - Ensure batch certification in compliance with EU GMP, Directive 2001/83/EC, national legislation, EU GMP Annex 16, the applicable

### Medical Director - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $295K-$339K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695371003
- Excerpt: Medical Director Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Medical Director in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The physician-scientist will focus on ensuring the accuracy, completeness, and integrity of clinical data supporting regulatory submissions (NDA, BLA, MAA). This role is uniquely positioned at the interface of clinical development, regulatory science, clinical data, and clinical operations, and will be instrumental in preparing pivotal datasets from the pivotal and supportive studies for successful global filings. The ideal candidate brings a strong foundation in clinical medicine (M.D. or equivalent), oncology experience, and proven expertise in clinical trial data review, cleaning, and regulatory submission preparation. The scope of data review and support activities spans early-stage clinical

### Director, Global Pre-Approval Patient Access - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $201K-$251K
- Posted: 2026-05-27
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7613323003
- Excerpt: Director, Global Pre-Approval Patient Access Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Global Pre-Approval Patient Access will lead the strategy, design, and execution of global early access programs for Revolution Medicines' pipeline. This role is critical to enabling appropriate patient access to investigational therapies targeting RAS-addicted cancers while ensuring alignment with clinical development/operations, regulatory requirements, and company priorities. This role will report into the Head of Advocacy and Society Engagement and play an integral role in our commitment to supporting appropriate patient access to medicines. - Develop and support global early access strategy aligned with clinical and regulatory milestones; ensure distinction with other patient access initiatives considered or implemented. - Design and implement free of charge named-patient and cohort early access programs globally. - Serve as overall cross-functional leader of the programs, liaising across Clinical, Regulatory, Medical Affairs, Commercial, Legal, Supply Chain, as needed. - Establish governance for global evaluation , and prioritization

### Director, Medical Science Liaison, (NY, Southern Connecticut) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734101003
- Excerpt: Director, Medical Science Liaison, (NY, Southern Connecticut) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various

### Director, Clinical Quality - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $201K-$251K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7693917003
- Excerpt: Director, Clinical Quality Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Clinical Quality will play a key role in Quality Assurance and have direct responsibility for the clinical quality workstreams and study teams. This role is responsible for providing quality and compliance oversight for RevMed-sponsored clinical trials with respect to RevMed's Standard Operating Procedures, applicable regulatory requirements (FDA, EU, ICH & country-specific), and current industry standards and practices. This role will support daily compliance operational activities, evaluate risk, and resolve quality events for early phase through late-phase clinical programs. This role will also be responsible for managing multiple studies including GLP activities that impact clinical studies/data. This role will report to the Head of Clinical Quality. - Act as the study lead for Phase 3 program(s), provide support and guidance to the Clinical Development and Clinical Operations functions, including but not limited to the following functional areas: Global Patient Safety, Translational Medicine,

### Director, Alliance Management - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-02-18
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7613271003
- Excerpt: Director, Alliance Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Alliance Management will serve as a key liaison between RevMed and its strategic partners, ensuring the success of collaborations across research and development. This role requires a dynamic leader with strong relationship management skills and the ability to drive alignment between internal teams and external stakeholders to achieve shared objectives. - Strategic Partnership Management: Oversee a variety of strategic alliances with industry and academic partners

### Director, Medical Science Liaison (AZ, CO, NM, NV) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739033003
- Excerpt: Director, Medical Science Liaison (AZ, CO, NM, NV) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in

### Research Associate II, Proteomics - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $91K-$110K
- Posted: 2026-05-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7750162003
- Excerpt: Research Associate II, Proteomics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and detail-oriented individual to support mass spectrometry-based proteomics workflows. This is an excellent opportunity for an early-career scientist to gain hands-on experience in proteomics within a drug discovery environment. This role will focus on executing established laboratory workflows, maintaining high-quality data standards, and supporting the development of new capabilities within the team. Training will be provided for specialized techniques and instrumentation. In this role, success will come from consistently executing workflows with accuracy, maintaining well-documented experiments, and building technical proficiency over time. As a key member of the Proteomics group within our dynamic Chemical Biology team, you will: - Perform sample preparation for bottom-up proteomics workflows using established protocols with high attention to detail and consistency. - Execute and help improve automated proteomics workflows. - Support routine instrument operation, maintenance and quality control of LC and MS/MS

### Director, Medical Science Liaison (IL, IN) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734099003
- Excerpt: Director, Medical Science Liaison (IL, IN) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases

### Director, Medical Science Liaison (NC, TN, KY, VA) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734089003
- Excerpt: Director, Medical Science Liaison (NC, TN, KY, VA) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in

### Director, Medical Science Liaison (Boston, RI, NH, VT, ME, CT(Yale)) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734097003
- Excerpt: Director, Medical Science Liaison (Boston, RI, NH, VT, ME, CT(Yale)) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence

### Director, Medical Science Liaison (OH, W. Virginia, W. PA, Upstate NY) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734093003
- Excerpt: Director, Medical Science Liaison (OH, W. Virginia, W. PA, Upstate NY) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of

### Director, Medical Science Liaison (Dallas, AR, LA, OK, MS) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739035003
- Excerpt: Director, Medical Science Liaison (Dallas, AR, LA, OK, MS) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved

### Associate Director, Clinical Quality Assurance - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-05
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7722995003
- Excerpt: Associate Director, Clinical Quality Assurance Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an Associate Director, Clinical Quality Assurance, who will play a key role within Quality Assurance and is responsible for providing leadership and compliance support for RevMed sponsored clinical trials with respect to RevMed's Standard Operating Procedures, applicable regulatory requirements (FDA, EU, ICH & country-specific), and current industry standards and practices. - Support the development and maintenance of applicable Quality Systems and procedures that comply with applicable GCP standards and guidelines. - Collaborate with clinical functions (e.g., Clinical Operations, Clinical Development) to provide GCP compliance support. - Participate in clinical study execution teams (CSETs) to enable risk-based quality management and a culture of quality and open dialogue. - Perform quality review of clinical trial documents with a focus on compliance / regulatory requirements and risk management. - Collaborate with internal stakeholders, external auditors, and auditees to support the planning,

### Director, Medical Science Liaison (ND, SD, NE, MO, IA, KS) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739061003
- Excerpt: Director, Medical Science Liaison (ND, SD, NE, MO, IA, KS) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence

### Director, Medical Science Liaison (Southern Florida, Puerto Rico) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734095003
- Excerpt: Director, Medical Science Liaison (Southern Florida, Puerto Rico) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in

### Director, Medical Science Liaison (Southern California) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734105003
- Excerpt: Director, Medical Science Liaison (Southern California) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases

### Director, Medical Science Liaison (Northern California, Hawaii) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734115003
- Excerpt: Director, Medical Science Liaison (Northern California, Hawaii) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various

### Director, Medical Science Liaison (Northern Florida, GA, SC, AL, MS) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734091003
- Excerpt: Director, Medical Science Liaison (Northern Florida, GA, SC, AL, MS) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence

### Senior Director, Payor and Health Systems Liaison, West - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $264K-$290K
- Posted: 2026-05-01
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7648509003
- Excerpt: Senior Director, Payor and Health Systems Liaison, West Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Payor and Health Systems Liaison will own and shape the scientific payer/access strategy for the US region. They will develop and cultivate relationships with key decision-makers and other influencers in managed care organizations, government programs, employers, hospital systems and product distribution companies, to support appropriate patient access and evidence-based utilization for Revolution Medicine's products. A key aspect of the Payor and Health Systems Liaison responsibilities is to keep payers and other key external constituents or influencers abreast of new product launches, line extensions and Medical Affairs research. The Payor and Health Systems Liaison leads high‑impact clinical, scientific, and population health engagement with external access stakeholders, including Payers, Group Purchasing Organizations (GPOs), Community Aggregators, and Integrated Delivery Networks (IDNs), while ensuring strong integration between Medical Affairs, HEOR, and Market Access strategy. Responsibilities

### Director, Medical Science Liaison (Philadelphia, Hershey, NJ, MD, DC) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734103003
- Excerpt: Director, Medical Science Liaison (Philadelphia, Hershey, NJ, MD, DC) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved

### Director, Medical Science Liaison Texas (Houston, Austin, San Antonio) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739068003
- Excerpt: Director, Medical Science Liaison Texas (Houston, Austin, San Antonio) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved

### Senior Director, Payor and Health Systems Liaison, East - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $264K-$290K
- Posted: 2026-05-01
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7711614003
- Excerpt: Senior Director, Payor and Health Systems Liaison, East Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Payor and Health Systems Liaison will own and shape the scientific payer/access strategy for the US region. They will develop and cultivate relationships with key decision-makers and other influencers in managed care organizations, government programs, employers, hospital systems and product distribution companies, to support appropriate patient access and evidence-based utilization for Revolution Medicine's products. A key aspect of the Payor and Health Systems Liaison responsibilities is to keep payers and other key external constituents or influencers abreast of new product launches, line extensions and Medical Affairs research. The Payor and Health Systems Liaison leads high‑impact clinical, scientific, and population health engagement with external access stakeholders, including Payers, Group Purchasing Organizations (GPOs), Community Aggregators, and Integrated Delivery Networks (IDNs), while ensuring strong integration between Medical Affairs, HEOR, and Market Access strategy. Responsibilities

### Executive Director, AI/ML Drug Discovery Analytics - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $326K-$383K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695158003
- Excerpt: Executive Director, AI/ML Drug Discovery Analytics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As Executive Director, AI/ML Drug Discovery Analytics, you will be a senior leader shaping the future of data-driven drug discovery at Revolution Medicines. You will define the Research's AI/ML strategy, oversee implementation of advanced analytics across discovery and build a world-class team to unlock the full potential of our rich internal datasets and make these insights accessible to other scientist. Your leadership will directly influence early discovery innovation, pipeline acceleration, and strategic portfolio decisions. Responsibilities include: Technical Leadership and Innovation: You will have a deep understanding of Machine Learning Operations and AI system design. Design and scale a robust ML infrastructure, integrating MLOps best practices to ensure seamless development, deployment, and monitoring of AI/ML models. Drive innovation in applying deep learning, generative models, and diffusion models to drug discovery, including target prediction, hit identification, and lead optimization. Leverage RevMed's unique datasets

### Senior Director, Responsible Pharmacist (Pharmacien Responsable), France - Revolution Medicines
- Location: Remote (France) (remote)
- Salary: Not disclosed
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7694372003
- Excerpt: Senior Director, Responsible Pharmacist (Pharmacien Responsable), France Remote (France) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: General Purpose The Senior Director, Head Pharmacist/Responsible Pharmacist guarantees the pharmaceutical responsibility of the laboratory as “exploitant” (see definition of the “exploitant”, Article R.5124-2, 3 ° of the French Public Health Code) and assumes the role of "Responsible Pharmacist" as described in Article R.5124-36 of the Public Health Code. Responsibilities include: - Organize and supervise all pharmaceutical operations of the company or organization, including manufacturing, advertising, information, pharmacovigilance, batch monitoring and withdrawal, distribution, import and export of the drugs, products, objects or articles concerned, as well as the corresponding storage operations. - Ensure that transport conditions guarantee the proper preservation, integrity and safety of these medicines, products, objects or articles. - Acknowledge the files related to marketing authorization applications submitted by Corporate or organization and any other application related to the activities they organize and supervise. - Participate in the development of research

### Associate Director, Clinical Operations Compliance & Training - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-04-29
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7684892003
- Excerpt: Associate Director, Clinical Operations Compliance & Training Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As an Associate Director, you will be responsible for the following: - Lead and/or support development and implementation of GCP systems and inspection readiness. - Lead and/or support the development and continuous improvement of Clinical Policies/ SOPs/ WIs/ Templates/etc. using knowledge and experience with clinical study management, International Conference on Harmonization (ICH) Guidelines, Good Clinical Practices (GCP) and regulatory requirements. - SME for

### Director, Medical Science Liaison (WA, OR, AK, MT, WY, ID, UT) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739050003
- Excerpt: Director, Medical Science Liaison (WA, OR, AK, MT, WY, ID, UT) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of

### Senior Manager, GMP Quality - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $164K-$205K
- Posted: 2026-06-03
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7762856003
- Excerpt: Senior Manager, GMP Quality Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Senior Manager, GMP Quality who will play a key role within Quality Assurance and is responsible for providing leadership and operational support for RevMed commercial programs, with a primary focus on commercial finished product batch review, disposition, and release activities in support of global product supply. Responsibilities: - Serve as the QA lead for commercial finished product (FP) batch review and disposition activities, ensuring timely and compliant release of commercial product for distribution. - Perform comprehensive review and approval of executed batch records, deviations, investigations, analytical data, Certificates of Analysis (CoAs), and associated release documentation for commercial product disposition. - Provide QA oversight for commercial manufacturing, packaging, labeling, testing, storage, and release operations performed at CMOs, contract laboratories, and distribution partners. - Collaborate cross-functionally with Pharmaceutical Development & Manufacturing (PDM/CMC), Supply Chain, Regulatory Affairs, Technical Operations, Validation, and

### Director, Medical Science Liaison (MI, WI, MN) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $236K-$259K
- Posted: 2026-05-14
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7734111003
- Excerpt: Director, Medical Science Liaison (MI, WI, MN) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various

### Director, Global Medical Excellence - Revolution Medicines
- Location: Basel, Basel-Stadt, Switzerland (unspecified)
- Salary: Not disclosed
- Posted: 2026-05-07
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7727888003
- Excerpt: Director, Global Medical Excellence Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Director, Global Medical Excellence, supporting the European region to serve as a key scientific and strategic partner to the Head of Global Medical Excellence. This role will help integrate and advance Medical Excellence initiatives across the portfolio for the European region by connecting science, strategy, and execution across the European regional Medical Affairs teams, in collaboration with the global teams. Key Responsibilities - Serve as a scientific thought partner to the Head of Global Medical Excellence, helping translate medical strategy into aligned Medical Excellence priorities. - Connect and integrate scientific themes, data narratives, and strategic objectives across Medical Excellence functions (e.g., publications, content & training, stakeholder engagement, analytics). - Support consistency and quality of scientific messaging and execution across global and regional Medical Affairs activities. Global-Regional Medical Partnership - Act as a key liaison between Global Medical Excellence and regional/local

### Associate Scientist, Research Laboratory Operations - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $119K-$149K
- Posted: 2026-06-05
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7757562003
- Excerpt: Associate Scientist, Research Laboratory Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an individual with a strong background in rodent laboratory animal research. The position will receive study designs from scientists and independently execute in vivo pharmacology studies in mice, while demonstrating excellent communication and coordination across teams. In addition, this role will support vivarium management, including management of weekend staff to ensure uninterrupted in vivo operations during weekends and holidays. - Plan, conduct, analyze, and report in vivo studies (efficacy, PK/PD). - Carry out pre-clinical model development and characterization. - Manage and supervise multiple research associates. - Conduct standard vivarium operations-managing inventory/supplies, maintain laboratory equipment, and record keeping. - Contribute to continuous improvement of current SOPS and ensure that the appropriate SOPs are followed by all Vivarium users. - Support adherence to animal welfare guidelines and regulations. - Learn and conduct other in vivo related techniques. - Train junior

### Scientist II, DMPK - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $132K-$166K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695463003
- Excerpt: Scientist II, DMPK Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The DMPK Scientist will be a key member of the Drug Metabolism and Pharmacokinetics (DMPK) team within the Nonclinical Development and Clinical Pharmacology (NDCP) department. Specifically, you will: - Design and execute in vitro and in vivo metabolite identification studies using liver microsomes, hepatocytes, recombinant enzymes, and biological samples (blood, plasma, tissue, urine, bile, etc.), and perform metabolite profiling and structural elucidation. - Characterize major, unique, or disproportionate metabolites to support candidate selection, MIST (Metabolites in Safety Testing) analysis, and metabolite regulatory strategy. - Design and perform mechanistic studies to understand metabolic pathways and enzyme kinetics; work with pharmaceutical product teams to characterize drug degradation products and impurities. - Author and review DMPK sections of regulatory submissions and respond to questions from regulatory agencies. - Build and maintain strong collaborative partnerships across functional areas, e.g., Discovery research, Clinical Pharmacology, Medicinal Chemistry, Pharmaceutical Development, Toxicology,

### Senior Director, Organizational Development & Effectiveness - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $244K-$305K
- Posted: 2026-04-22
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7711168003
- Excerpt: Senior Director, Organizational Development & Effectiveness Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and enterprise-minded leader to build and scale the Organizational Development and Effectiveness function at Revolution Medicines. As Senior Director, Organizational Effectiveness, you will define and drive the long-term strategy for leadership effectiveness, team performance and organizational health to support our rapid growth and strengthen our mission-driven, values-aligned culture. This role partners closely with HR Business Partners, Learning & Development and Senior Leaders across all functions and regions to deliver high-impact organizational programs and solutions to drive team effectiveness. You will design a scalable, data-informed approach that leverages both internal capabilities and an external network of coaches and facilitators to meet evolving business needs. This function will ensure that leaders and teams are equipped to operate effectively at scale, while providing clear insights and interventions that enhance organizational performance across the enterprise. The function will lead both

### Executive Director, Healthcare Law and Market Access - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $311K-$357K
- Posted: 2026-06-02
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7648505003
- Excerpt: Executive Director, Healthcare Law and Market Access Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an Executive Director, Healthcare Law and Market Access reporting to the Vice President, Healthcare Law to join our RevMed team. The Executive Director, Healthcare Law and Market Access will serve as the zoldonrasib Legal brand lead and provide strategic legal guidance related to the company's planned zoldonrasib commercialization activities, patient access programs, distribution and licensing, and regulatory submissions. In addition, the position will serve as the senior enterprise legal leader responsible for shaping and advancing Revolution Medicines' U.S. Market Access legal strategy in support of commercialization, patient access, pricing, reimbursement, and corporate growth objectives. At a tactical level, the position will be responsible for managing all aspects of Market Access contracting through product distribution channels, including distributors, specialty distributors, specialty pharmacies, 3 rd party logistics providers and payers, and government pricing and reimbursement. A successful candidate will

### Senior Director, Medical Affairs, France - Revolution Medicines
- Location: Paris, France (unspecified)
- Salary: Not disclosed
- Posted: 2026-04-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7717880003
- Excerpt: Senior Director, Medical Affairs, France Paris, France Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, France the Senior Director, Medical Affairs, France is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the French Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that French medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the French medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for France, accountable for local medical strategy, execution, and impact

### Clinical Program Manager - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $143K-$178K
- Posted: 2026-05-06
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7725030003
- Excerpt: Clinical Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Clinical Program Manager (CPM), you will be responsible for acting as a central contact for the Clinical Study Team(s) and assist with the execution and management of Revolution Medicines (RevMed) clinical trials. - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed. - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. - Conduct risk

### Vice President, Patents - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $354K-$408K
- Posted: 2026-04-11
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7697205003
- Excerpt: Vice President, Patents Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished and highly strategic patent attorney to lead intellectual property strategy for our patent portfolio. This role is designed for a senior expert who can operate at the intersection of sophisticated patent prosecution and patent disputes within one of the most competitive areas in oncology. Reporting to the VP of IP, this individual will serve as our patent portfolio lead, with responsibility for developing and integrating global prosecution and challenge (both offensive and defensive) strategies. The role will function as a key strategic partner to the VP and a trusted advisor to senior leadership, with a primary focus on strengthening the durability and value of company assets worldwide, anticipating competitive threats, and identifying and mitigating vulnerabilities. This position may include management responsibility for members of the IP team, such as those handling patent prosecution. However, people management is not required

### Senior Research Associate, Proteomics - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $106K-$126K
- Posted: 2026-05-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7750316003
- Excerpt: Senior Research Associate, Proteomics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and detail-oriented individual to support and advance mass spectrometry-based proteomics workflows. This role is well-suited for a scientist with prior industry experience who is excited to apply and expand their expertise in proteomics within a drug discovery environment. This position will involve executing and optimizing laboratory workflows, maintaining high-quality data standards, and contributing to the development of new capabilities within the team. The ideal candidate will demonstrate strong technical proficiency, attention to detail, and the ability to work both independently and collaboratively. In this role, success will come from consistently delivering high-quality, reproducible data, maintaining well-documented experiments, and proactively identifying opportunities to improve workflows and efficiency. As a key member of the Proteomics group within our dynamic Chemical Biology team, you will: - Perform sample preparation for bottom-up proteomics workflows with high attention to detail and reproducibility.

### Senior Counsel, Pharmaceutical Development and Manufacturing - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $244K-$282K
- Posted: 2026-05-12
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7613277003
- Excerpt: Senior Counsel, Pharmaceutical Development and Manufacturing Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: RevMed is seeking an experienced attorney to support our global manufacturing, supply chain, and technical operations activities. This role will lead the drafting, negotiation, and management of complex agreements with contract development and manufacturing organizations (CDMOs), raw material suppliers, and other third-party vendors critical to drug development and commercialization. The ideal candidate has deep experience in biotech or pharmaceutical contracting, a strong understanding of GMP and regulatory considerations, and the ability to partner effectively with business, technical, and quality teams. A successful candidate will bring proven experience working at a publicly traded life sciences organization, with demonstrated success in driving legal cross-functional strategy. Your Contributions (include, But Are Not Limited To) - Draft, review, and negotiate a wide range of manufacturing-related agreements, including: - CDMO master services agreements and work orders - Manufacturing and supply agreements - Quality agreements (in coordination

### Senior Director, HEOR/RWE GI - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $244K-$305K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695585003
- Excerpt: Senior Director, HEOR/RWE GI Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, HEOR/RWE is a leader within the organization, responsible for developing an HEOR/RWE strategy and executing HEOR plans and activities related to Revolution Medicines assets intended for use in pancreatic and colorectal cancer. They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally. The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans. This individual

### Medical Director, Early-Stage Clinical Development - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $295K-$339K
- Posted: 2026-04-09
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7693796003
- Excerpt: Medical Director, Early-Stage Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Medical Director of Clinical Development in support of Revolution Medicines' molecule(s) in clinical or late pre-clinical development. In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research and may extend to studies supporting regulatory submissions including Breakthrough-Therapy-Designation (BTD) or Accelerated Approvals (AA). You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science and medical aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as

### Director, Supply Chain & Wholesaler Relations - Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-05-21
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7743097003
- Excerpt: Director, Supply Chain & Wholesaler Relations - Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Japan Supply Chain & Wholesaler Relations will play a critical role in building Revolution Medicines' Japan commercial supply chain infrastructure from the ground up to ensure operational readiness for commercial launch and ongoing supply continuity. This is a highly hands-on role requiring both strategic thinking and operational execution. The successful candidate will personally lead wholesaler selection, contract negotiations, 3PL setup, distribution process design, and launch readiness activities in close collaboration with QA, CMC, Regulatory, Finance, and Commercial teams. We are seeking an agile and entrepreneurial leader who thrives in a fast-paced biotech environment and is comfortable operating with limited infrastructure and evolving processes. This role is best suited for individuals who have experience building new capabilities rather than operating within highly structured large-company environments. The ideal candidate combines deep knowledge of the Japanese pharmaceutical distribution landscape with the ability to

### Associate Director, Discovery Process Chemistry - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695499003
- Excerpt: Associate Director, Discovery Process Chemistry Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated individual with a scientific background to play a critical role as a technical leader within the CRO management team in the Medicinal Chemistry function. This position will be responsible for route evaluation and enabling the CRO team to perform reaction condition optimization, and scale-up of key intermediates to support Revolution Medicines Medicinal Chemistry efforts. The qualified candidate will be responsible for enabling the rapid transition of the Medicinal chemistry routes to PDM process chemistry development, the effective communication and collaboration with CRO teams and PDM and leading efficient transitional efforts to enable the PDM team. This role is reporting to the Director of CRO management, Medicinal Chemistry. Responsibilities: - Work closely with discovery chemistry teams and monitor the progress of the projects and provide support on material needs of building blocks and intermediates and solutions of

### Executive Director, Global Patient Safety Quality and Compliance - Pharmacovigilance - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $265K-$331K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695212003
- Excerpt: Executive Director, Global Patient Safety Quality and Compliance - Pharmacovigilance Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a skilled and experienced Executive Director (ED) of Global Patient Safety (GPS) Quality and Compliance to join our dynamic team. The ED GPS Quality and Compliance is responsible for the strategy, development, oversight, and execution of the pharmacovigilance quality management system (PV-QMS) within the organization. This role ensures the safety of patients and the overall positive benefit-risk of RevMed pharmaceutical products by driving compliance with global pharmacovigilance regulations and fostering a culture of safety and vigilance. The responsibilities of this role include oversight of the PV-QMS , PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. The ED of GPS Quality

### Senior Director, Medical Affairs, Midsized Markets Europe - Revolution Medicines
- Location: Basel, Basel-Stadt, Switzerland (unspecified)
- Salary: Not disclosed
- Posted: 2026-05-05
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7725127003
- Excerpt: Senior Director, Medical Affairs, Midsized Markets Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, GM, Midsized Markets, the Senior Director, Medical Affairs, Midsize Markets Europe, is the medical leader responsible for defining and executing the medical strategy for oncology products in our portfolio within Midsized markets. This role serves as the medical voice within the Midsized markets Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Midsized markets medical considerations are embedded in the regional medical strategy and plans and will partner with the Midsized markets country managers and crossfunctional teams, as well as VP Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Midsized markets medical team and working closely with the Global, Regional, Country Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as

### Director, Molecular Pathology, Translational Sciences, Translational Research. - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695103003
- Excerpt: Director, Molecular Pathology, Translational Sciences, Translational Research. Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: - Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies. - Integration of Advanced Modalities: Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs. - Digital & Computational Pathology: Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making. - Data Interpretation & Reporting: Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights. - Cross-functional Leadership: Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies. Responsibilities - Scientific Leadership

### Director, Clinical Pharmacology - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-05-22
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7747200003
- Excerpt: Director, Clinical Pharmacology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and energetic individual with a relevant scientific background to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) Organization. As a key member of the Clinical Pharmacology group, you will: - Represent the clinical pharmacology function in project teams and build strong working relationships with cross-functional teams to impact critical decisions. - Responsible for clinical pipeline delivery through major milestones including IND/CTA, EOP2, and marketing applications NDA/sNDA. - Lead the design and execution of an integrated clinical pharmacology and modeling and simulation strategy to guide the clinical development plan. - Apply state-of-the-art quantitative pharmacology analyses, including population PK, exposure-response analyses, to guide dose/schedule selection and recommended phase 2 dose and schedule (RP2Ds) selection. - Author and provide technical input for regulatory documents and submissions related to all aspects of clinical pharmacology (including protocol, CSR, IB, briefing package,

### Senior Director, Real World Data & Analytics - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $244K-$305K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695619003
- Excerpt: Senior Director, Real World Data & Analytics Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Real-World Data & Analytics will work with the Executive Director, Head of Epidemiology and VP of HEOR to establish the RWD&A group at RevMed, scaling organizational capabilities and leading the strategy and execution of key RWD&A deliverables for RevMed assets. They will be accountable for working across the clinical development, safety, medical affairs, commercial including analytics and insights, and IT matrix, developing strategies and leading and/or overseeing execution of key projects. Reporting to the Executive Director, Head of Epidemiology & RWD Strategy, they will closely align with the other users of RWD at RevMed, develop ways of working and communication channels to maximize RevMed's investment in RWD as well as lead the analysis (either directly or leveraging junior team members and vendors) of RWD database and other studies. This is an exceptional opportunity to contribute to the advancement of

### Associate Director, Global Omnichannel Solutions Delivery - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-22
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7655280003
- Excerpt: Associate Director, Global Omnichannel Solutions Delivery Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: RevMed is seeking a strategic and experienced technology leader to join our Information Sciences (IS) team as Associate Director, Global Omnichannel Solutions Delivery. This role will ensure our omnichannel technology ecosystem is connected, scalable, and globally ready, enabling seamless customer experiences across markets outside of the US. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation. The ideal candidate brings strong technical acumen, experience working across multiple marketing technologies, and the ability to translate complex business needs into scalable, globally consistent solutions. Key responsibilities: Global Omnichannel Enablement - Lead deployment of integrated customer journeys across ex-US markets, ensuring alignment with global platform strategy. - Enable launch, medical, and global expansion priorities through scalable solution enablement.

### Executive Director, Patents - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $315K-$362K
- Posted: 2026-04-11
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7648503003
- Excerpt: Executive Director, Patents Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished and highly strategic patent attorney to lead intellectual property strategy for our patent portfolio. This role is designed for a senior expert who can operate at the intersection of sophisticated patent prosecution and patent disputes within one of the most competitive areas in oncology. Reporting to the VP of IP, this individual will serve as our patent portfolio lead, with responsibility for developing and integrating global prosecution and challenge (both offensive and defensive) strategies. The role will function as a key strategic partner to the VP and a trusted advisor to senior leadership, with a primary focus on strengthening the durability and value of company assets worldwide, anticipating competitive threats, and identifying and mitigating vulnerabilities. This position may include management responsibility for members of the IP team, such as those handling patent prosecution. However, people management is not required

### Director, Safety Management, Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-05-15
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7694312003
- Excerpt: Director, Safety Management, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Director level professional to lead safety management activities for its Japan entity and to serve as the Safety Management Manager (Anseki) under Japanese regulations. The Safety Management Lead is responsible for establishing and overseeing safety management activities for the Japan entity and supporting the establishment and maintenance of the Japan Marketing Authorization Holder (MAH). In this role, the Safety Management Lead is also responsible for ensuring that all relevant pharmacovigilance requirements for Revolution Medicines are fulfilled. The role operates as part of the legally required three-role framework, working in close collaboration with Marketing Supervisor General (Soseki) and Quality Assurance Manager (Hinseki) to ensure effective governance across safety, quality, and regulatory domains. Key Responsibilities: - Accountable for maintaining compliance with PMDA, PV Agreements, and the Japanese Risk Management Plan (J-RMP). - Lead the design, implementation, and maintenance of the safety management system

### Director, Regulatory Affairs (Global Filing Lead) - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695128003
- Excerpt: Director, Regulatory Affairs (Global Filing Lead) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Regulatory Affairs (Global Filing Lead) is accountable for driving preparation & execution of global regulatory NDA/MAA filings for late-stage oncology programs at RevMed. They will manage end-to-end execution of the dossier, ensuring cross-functional coordination and effective communication across Regulatory, Clinical, Biostatistics, CMC, Quality, Translational Medicine and Commercial. The Director will support drug development teams and ensure delivery of targeted, pragmatic, well-vetted, consistent and actionable regulatory advice. The Director must have a thorough understanding and be highly experienced in oncology drug development, US NDA & global filing regulations, current Health Authority thinking, and have strong leadership & problem-solving ability. Reports into Regulatory Affairs, Global Filing & Registration - High-Impact position to lead cross-functional development & regulatory submission activities for registrational oncology programs in the EU, UK, Japan and internationally. - Collaborate closely with Program Teams and Global Regulatory Leads

### Principal Machine Learning Scientist, Drug Discovery Analytics - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $273K-$321K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695388003
- Excerpt: Principal Machine Learning Scientist, Drug Discovery Analytics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Machine Learning Scientist to lead the development of advanced machine learning approaches that accelerate small-molecule drug discovery. This role sits at the intersection of data science, chemistry, and biology, transforming complex scientific datasets into predictive models that guide target discovery, compound design, and translational hypotheses. Working closely with experimental scientists, the Principal ML Scientist will develop cutting-edge modeling approaches that integrate chemical, biological, and phenotypic data. The successful candidate will play a key role in advancing a data-driven discovery strategy by designing predictive models, deploying innovative algorithms, and translating insights into actionable decisions that improve the speed and success of the discovery of medicines for patients with RAS-driven cancers. Key responsibilities include: Scientific Leadership: - Define and lead machine learning strategies that accelerate early-stage drug discovery. - Identify opportunities where AI and advanced analytics can

### Manager, Commercial Supply Chain - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $143K-$178K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7738630003
- Excerpt: Manager, Commercial Supply Chain Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and experienced Manager, Commercial Supply Chain to lead and optimize global distribution and logistics operations supporting commercial pharmaceutical products. This role is responsible for ensuring the compliant, timely, and efficient movement of GMP materials and finished goods across manufacturing sites, depots, CMOs, and 3PL partners. The successful candidate will partner cross-functionally to support commercial scale-up, global distribution expansion, and supply continuity initiatives while driving operational excellence, compliance, and continuous improvement across the commercial supply chain network. Responsibilities: - Plan and execute global distribution and end-to-end logistics operations for commercial products across manufacturing sites, CMOs, depots, and 3PL partners, ensuring compliant shipment execution, documentation, carrier coordination, and on-time delivery performance. - Oversee GMP and temperature-controlled product movements while managing excursions, deviations, investigations, and CAPAs in partnership with Quality. - Manage global trade compliance programs, including import/export controls, customs

### Senior Product Manager, Chemistry - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7738675003
- Excerpt: Senior Product Manager, Chemistry Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Senior Product Manager, Chemistry to deliver products and capabilities that help Chemistry teams make faster, higher-confidence design and progression decisions in oncology-focused drug discovery. This role will define and deliver the product strategy for Chemistry workflows, data products, and AI-enabled decision support using the right mix of internal product development, SaaS platforms, vendor partnerships, integrations, and RevCore capabilities. You will partner with medicinal chemists, synthetic chemists, computational chemists, analytical chemists, DMPK and Biology partners, Data Science, ML Engineering, Data Engineering, IT, and platform teams to turn complex Chemistry workflows into intuitive, scalable solutions that accelerate the Design-Make-Test-Learn cycle. Own Chemistry product strategy - Define the vision and roadmap for Chemistry products and capabilities across medicinal chemistry, synthetic chemistry, analytical chemistry, compound management, and the Design-Make-Test-Learn cycle. - Build a Now, Next, Later roadmap from foundational compound data capabilities to

### Senior Manager, Medical Science Liaison, Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-06-09
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7767672003
- Excerpt: Senior Manager, Medical Science Liaison, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison (MSL). Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Reporting to JP Regional Medical Science Liaison (JPR MSL), MSLs are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence

### Senior Director, Medical Affairs, UK - Revolution Medicines
- Location: London, England, United Kingdom (unspecified)
- Salary: Not disclosed
- Posted: 2026-04-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7717896003
- Excerpt: Senior Director, Medical Affairs, UK London, England, United Kingdom Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, UK the Senior Director, Medical Affairs, UK is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the UK Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that UK medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the UK medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for UK, accountable for local medical strategy, execution,

### Senior Medical Director, Early-Stage Clinical Development - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $346K-$397K
- Posted: 2026-04-30
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7720237003
- Excerpt: Senior Medical Director, Early-Stage Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Medical Director of Clinical Development in support of Revolution Medicines' molecule(s) in clinical or late pre-clinical development. In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research and may extend to studies supporting regulatory submissions including Breakthrough-Therapy-Designation (BTD) or Accelerated Approvals (AA). You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science and medical aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel,

### Director, Regulatory Affairs - US Filing Lead - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695137003
- Excerpt: Director, Regulatory Affairs - US Filing Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Regulatory Affairs (US Filing Lead) is accountable for driving preparation & execution of Regulatory NDA/MAA filings for late-stage oncology programs at RevMed. They will manage end-to-end execution of the dossier, ensuring cross-functional coordination and effective communication across Regulatory, Clinical, Biostatistics, CMC, Quality, Translational Medicine and Commercial. The Director will support drug development teams and ensure delivery of targeted, pragmatic, well-vetted, consistent and actionable regulatory advice. The Director must have a thorough understanding and be highly experienced in oncology drug development, US NDA regulations, current Health Authority thinking, and have strong leadership & problem-solving ability. Reports into Regulatory Affairs, Global Filing & Registration - High-Impact position to lead cross-functional development & regulatory submission activities for registrational oncology programs in the US. - Collaborate closely with Program Teams and Global Regulatory Leads to advance effective & consistent regulatory strategies

### Senior Director, Medical Affairs, Spain - Revolution Medicines
- Location: Remote (Spain) (remote)
- Salary: Not disclosed
- Posted: 2026-04-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7717891003
- Excerpt: Senior Director, Medical Affairs, Spain Remote (Spain) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, Spain the Senior Director, Medical Affairs, Spain is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the spanish Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Spanish medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the spanish medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for Spain, accountable for local medical strategy, execution, and impact

### Senior Specialist, Procure to Pay, Europe - Revolution Medicines
- Location: Basel, Basel-Stadt, Switzerland (unspecified)
- Salary: Not disclosed
- Posted: 2026-06-04
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7763963003
- Excerpt: Senior Specialist, Procure to Pay, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines Switzerland is seeking a motivated individual with a background in the life sciences industry to play a critical role in the accounting team. Reporting to the Senior Manager, Accounts Payable Europe, this newly created role will support the daily procure to pay operations across multiple European entities while ensuring accurate processing, adherence to internal controls and compliance with US GAAP and local statutory requirements. This role ensures accurate, timely, and compliant processing of purchase orders, vendor invoices, vendor payments, employee expense reimbursements and VAT filings while driving process improvements, standardization, and strong internal controls across the region. The role is located in Basel, Switzerland. - Ensure timely and accurate processing for vendor onboarding, vendor purchase orders, invoices, employee expense reports, and payments - Review invoice coding for correct legal entity, department, account, location and tax treatment. - Coordinate or support payment

### Principal Product Manager, Real World Evidence Intelligence - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7738983003
- Excerpt: Principal Product Manager, Real World Evidence Intelligence Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Product Manager, Real-World Evidence Intelligence to shape products and capabilities that help teams use real-world data to design better studies, evaluate feasibility, support regulatory and evidence strategies, communicate value, and monitor outcomes across the product lifecycle. This role will define and deliver RWE Intelligence capabilities through the right mix of internal products, RevCore platform capabilities, external data assets, SaaS platforms, vendor partnerships, and integrations. The mandate is to improve study design, protocol feasibility, enrollment assumptions, external comparator readiness, evidence generation speed, value communication, and post-approval monitoring. You will work on high-impact capabilities where data fitness, transparency, reproducibility, and speed directly affect clinical development decisions, regulatory confidence, access strategy, and patient impact. Own RWE Intelligence strategy and measurable outcomes - Define the vision and roadmap for RWE products and capabilities across clinical development, regulatory, medical, HEOR,

### Associate Director, Biostatistics – Early Phase - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-04-23
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7712274003
- Excerpt: Associate Director, Biostatistics – Early Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This position is to serve as a study level statistician for oncology studies, and to coordinate activities with other functional groups to ensure timely deliverables. - Represent biostatistics on study/project teams. - Provide statistical expertise for design, analysis and reporting of clinical studies. - Collaborate with various functions on study design and planning, protocol development, statistical methodology and analysis. - Develop statistical analysis plans and analysis specifications. - Collaborate with statistical programming to ensure that analysis is conducted per statistical plan and specifications. - Collaborate with data management and clinical operations to ensure robust CRF and database development and quality data collection. - Provide statistical input to regulatory interaction and response to health authority submissions. - Collaborate in publications, assist in data interpretation, and ensure consistency and accuracy in data presentation. - Contribute to the development of functional-level standards, SOPs, and

### Principal Scientist, Cancer Pharmacology, Translational Research - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $190K-$238K
- Posted: 2026-05-21
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7746574003
- Excerpt: Principal Scientist, Cancer Pharmacology, Translational Research Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Principal Scientist in the Cancer Pharmacology team within the Translational Research group, in the Biomedical Discovery Research Department, you will: - Provide scientific and strategic leadership for RAS(ON) inhibitor programs by translating mechanistic insights in RAS biology into impactful pharmacology strategies and translational study plans. - Lead, mentor, and develop a high-performing group of in vivo scientists, fostering scientific excellence, innovation, and cross-functional collaboration. - Drive the design, execution, and interpretation of in vivo efficacy and PK/PD studies conducted internally and through external partners to advance oncology discovery and development programs. - Partner closely with the cross-functional quantitative modeling group to provide biological insight, translational context, and critical evaluation supporting PK/PD modeling efforts. - Influence portfolio progression through generation of high-impact data packages and contributions to regulatory submissions. - Serve as the in vivo pharmacology expert on cross-functional project

### Senior Director, Medical Affairs, Italy - Revolution Medicines
- Location: Remote (Italy) (remote)
- Salary: Not disclosed
- Posted: 2026-04-28
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7717894003
- Excerpt: Senior Director, Medical Affairs, Italy Remote (Italy) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, Italy the Senior Director, Medical Affairs, Italy is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the Italian Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Italian medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Italian medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for Italy, accountable for local medical strategy, execution, and impact

### Director, Stability Management, Analytical Development and Quality Control - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-23
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7712471003
- Excerpt: Director, Stability Management, Analytical Development and Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a critical role as the stability program lead, the position will be responsible for oversight and management of outsourced stability studies conducted. The director, stability is a self-motivated individual who works as a member of an integrated team contracting, designing, managing, and evaluating stability studies at contractors for both drug substance and drug product. This individual should have the breadth of experience required to manage stability studies in commercial, late and early clinical development stage. This individual should have broad knowledge of ICH and cGMP guidelines and the ability to contribute to global regulatory filings for stability. - Develop and implement the strategic direction of stability programs in alignment with ICH guidelines and regulatory expectations. - Oversee the design, execution, and management of stability studies (development, registration and commercial). - Work cross functionally with CMC, quality, regulatory, clinical

### Executive Director, Early Clinical Development - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $265K-$331K
- Posted: 2026-05-15
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7720361003
- Excerpt: Executive Director, Early Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced drug developer and effective leader to serve as Executive Director of Early Clinical Development in support of Revolution Medicines' clinical-stage molecule(s) and/or pre-clinical molecule(s). In this critical role, you will be responsible for developing the strategic plans and ensuring efficient operational execution of the molecule(s)' clinical development program in one or more disease indications, from early-stage studies to regulatory submissions and potential commercialization. You will play a pivotal role in shaping the future of our pipeline and driving the development of transformative therapies for patients. - Provide critical insights/contributions and implement comprehensive/execute upon the clinical development plans for Revolution Medicines' molecules, ensuring alignment with scientific, regulatory, and commercial objectives. - Lead, mentor, and manage a high-performing cross-functional team of clinical development professionals, fostering a culture of collaboration, innovation, and excellence. - Oversee all aspects of clinical trial

### Director, CMC Regulatory, Europe - Revolution Medicines
- Location: Basel, Basel-Stadt, Switzerland (unspecified)
- Salary: Not disclosed
- Posted: 2026-04-20
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7708726003
- Excerpt: Director, CMC Regulatory, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As part of our expanding European organization, we seek a strategic and hands-on Director, CMC Regulatory, Europe who will be responsible for developing and executing regional CMC regulatory strategies to support early development, marketing authorizations, and lifecycle management across Europe. This role is responsible for ensuring successful interactions with the European Medicines Agency (EMA), national competent authorities (NCAs), and other regional regulatory bodies. It provides leadership across early- and late-stage CMC regulatory activities, including clinical trial applications, initial marketing authorization applications (MAA), post-approval variations, and lifecycle strategy. The position requires deep expertise in EU regulatory frameworks, strong cross-functional collaboration, and the ability to proactively identify and manage regulatory risks while supporting business objectives. Primary Responsibilities: - Provide CMC regulatory support for clinical trial applications and regulatory interactions, ensuring alignment with EU requirements and timelines. - Develop and lead execution of European CMC regulatory strategies to

### Associate Director, HEOR, Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-06-09
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7767687003
- Excerpt: Associate Director, HEOR, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, HEOR Japan will provide execution, and scientific leadership across health economics, outcomes research, and real-world evidence (RWE) to optimize the value demonstration of Revolution Medicines oncology portfolio across JPAC markets. They will work in concert with Global HEOR and other regional teams to deliver an Integrated Evidence Plan for each asset and disease area. The role will align HEOR evidence generation with market access, pricing & reimbursement, patient access strategies, and cross-functional planning. The Associate Director, HEOR Japan will report to the Executive Medical Director, Japan and a dotted line into the Global HEOR group. Key Responsibilities - Strategic Leadership: Define, drive and deliver upon a HEOR strategy within Japan in support of product lifecycle planning, value evidence generation, pricing/reimbursement, and access engagements. They will be accountable for delivering value demonstration - Integrated Evidence Planning: Participate within the Revolution Medicines IEP process and

### Senior Director, Biostatistics, Europe - Revolution Medicines
- Location: Remote (Switzerland) (remote)
- Salary: Not disclosed
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7694347003
- Excerpt: Senior Director, Biostatistics, Europe Remote (Switzerland) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and the subject matter expert (SME) in Biostatistics within the Quantitative Sciences function, this position is to provide statistical leadership and support for EU access strategies, healthcare technology assessments and regulatory submissions. - Serve as the statistical lead for European access strategies, ensuring alignment between Global Clinical Development, European regulatory (EMA, MHRA, Swissmedic...) and regional/local Market Access needs to support successful European launches in collaboration with global and regional crossfunctional teams. - Partner with Regional and Local Market Access and HEOR functions to design and lead/oversee the execution of statistical analyses required for value dossiers, including PICO, indirect treatment comparisons, network meta-analyses, and RWE generation. - Partner closely with the development statistical lead, provide statistical support for EU regulatory interactions, including EMA Scientific Advice, MAA, Type II variations, and post-authorization commitments. - Ensure statistical methodologies

### Senior Director, Commercial Drug Product Manufacturing Operations - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $244K-$305K
- Posted: 2026-06-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7757586003
- Excerpt: Senior Director, Commercial Drug Product Manufacturing Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial Drug Product Manufacturing Operations will lead commercial drug product manufacturing and primary packaging activities within the Drug Product Development & Manufacturing organization. The role will oversee execution of commercial manufacturing operations across external manufacturing and packaging partners to support reliable commercial supply and lifecycle management. Responsibilities include commercial readiness activities, site qualification, technology transfer, process validation, PPQ execution, post-approval changes, troubleshooting, continued process verification (CPV), and operational excellence initiatives. The role will also support execution of commercial process monitoring activities to ensure sustained process performance and product quality. Responsibilities: - Lead execution of commercial manufacturing and primary packaging operations across CMOs and packaging partners. - Lead implementation of post-approval manufacturing and packaging changes. - Lead execution of continued process verification (CPV) activities across commercial manufacturing operations. - Manage monitoring and trending of critical process parameters, process

### Senior Scientist I, Clinical Biomarker Development - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $149K-$186K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695669003
- Excerpt: Senior Scientist I, Clinical Biomarker Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Scientist I in Clinical Biomarker Development team, within the Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline. You will: - Design and execute clinical biomarker strategies to support early response monitoring, patient stratification, and understanding resistance mechanisms. - Support biomarker implementation for early- and late-stage oncology clinical trials. - Oversee biomarker assay development, qualification, and sample analysis in collaboration with internal teams and external CROs. - Analyze and interpret biomarker data in the context of clinical outcomes and present results to cross-functional teams. - Contribute to clinical protocols, study reports, and regulatory documents (e.g., INDs, IBs, CSRs). - Translate preclinical findings into clinically actionable biomarker hypotheses. - Stay current with emerging biomarker technologies and trends in precision oncology. Required Skills, Experience and Education: - PhD

### Senior Medical Director - Late Phase - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $346K-$397K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7697171003
- Excerpt: Senior Medical Director - Late Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Medical Director in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The physician-scientist will focus on ensuring the accuracy, completeness, and integrity of clinical data supporting regulatory submissions (NDA, BLA, MAA). This role is uniquely positioned at the interface of clinical development, regulatory science, clinical data, and clinical operations, and will be instrumental in preparing pivotal datasets from the pivotal and supportive studies for successful global filings. The ideal candidate brings a strong foundation in clinical medicine (M.D. or equivalent), oncology experience, and proven expertise in clinical trial data review, cleaning, and regulatory submission preparation. The scope of data review and

### Associate Director, Tax - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-12
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7732675003
- Excerpt: Associate Director, Tax Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated individual with a tax background to play a critical role as a Associate Director of Tax within the finance department. Partnering with the Senior Director of Tax and finance team, the Associate Director will support global tax strategy, provision, and compliance, acting as a key cross-functional collaborative partner with R&D, international, and commercial teams to achieve business goals and meet the financial obligations of the organization. The role is an individual contributor reporting to the Senior Director of Tax and will work closely with external tax advisors, auditors, and internal stakeholders. Current tax department of two, with the possibility of expanding the team as the company advances. Responsibilities include: - Assist in the management and development of Company's international, US and state tax strategy. - Assist with and/or drive the research of complex tax technical topics, ultimately positioning

### Senior Manager, Marketing, Lung - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $150K-$189K
- Posted: 2026-06-09
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7767420003
- Excerpt: Senior Manager, Marketing, Lung Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Senior Marketing Manager, you will be a key contributor to the development of compelling omnichannel campaigns that promote Revolution Medicine's values, scientific innovation, and patient centricity. You will develop and execute marketing strategies and plans to achieve brand objectives and growth targets, particularly for non-personal promotion initiatives. Identification and implementation of innovative digital promotion technologies will be essential to this role. You will also collaborate cross-functionally and support media planning, campaign measurement, campaign asset promotional review, and related expense budgets. - Engages in strategic market planning through developing and executing marketing strategies for lung cancer products and indications. - Understands customer needs and preferences to create engaging and effective marketing campaigns. - Oversees the execution of marketing campaigns across various channels, including digital, print, and field-based resources. - Tracks and analyzes marketing campaign performance to identify areas for improvement and provide recommendations for

### Senior Manager, Global Patient Safety Operations - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $164K-$205K
- Posted: 2026-05-13
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7733787003
- Excerpt: Senior Manager, Global Patient Safety Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This position will be responsible for the management, development, and oversight of Global Patient Safety operational activities in the execution of safety information collection and reporting for the assigned Revolution Medicines' clinical programs. - Participates in the development of Global Patient Safety Operations operational objectives, policies, and procedures. - Represent Global Patient Safety in different cross functional team meetings. - Collaborate with other functional groups to achieve clinical program goals. - Oversee Pharmacovigilance Contract Research Organization (PV CRO) in the execution of safety reporting in clinical studies. - Manage PV CROs to ensure compliance with required timelines, that potential issues are being communicated, and resolution is achieved in a timely manner. - Oversee reporting of safety reports to global regulatory authorities, central IRB/ethics committees, investigators to ensure compliance with global regulatory requirements. - Ensure timely and accurate set up of global

### Scientist I, Quantitative Systems Pharmacologist - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $119K-$149K
- Posted: 2026-05-08
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7727990003
- Excerpt: Scientist I, Quantitative Systems Pharmacologist Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a QSP modeling & simulation scientist to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) organization. This position will be responsible for developing, validating, and executing modeling projects with a focus on mechanistic PBPK-QSP mathematical models for small molecule programs to increase mechanistic understanding of compound PK behavior and drug distribution, pharmacological effects on RAS targets, support clinical translation, and drive future discovery and development efforts. As a Quantitative Systems Pharmacologist, you will: - Develop, validate, execute, and refine quantitative systems pharmacology (QSP) models, minimal physiologically based pharmacokinetic (PBPK) models, semi-mechanistic PK/PD models, and tumor growth models to support development and discovery phase projects including next-generation inhibitor design and assessment of combination potential. - Propose and perform in silico simulations to answer complex mechanistic questions, create data visualizations to effectively communicate modeling results to a wide-ranging audience,

### Associate Director, Learning & Engagement - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-27
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7749061003
- Excerpt: Associate Director, Learning & Engagement Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is an exciting opportunity to lead the Learning & Engagement initiatives. The Associate Director, Learning & Engagement will lead the design, development and implementation of learning initiatives, instructional design solutions, learning forums, and infrastructure initiatives across partnered functions and in close alignment with HR and RevMed Learning and Engagement functions' best practices. This role requires a blend of Learning & Development expertise, a solid understanding of drug development processes & skillsets, and the communication abilities to support a diverse portfolio of strategic growth initiatives. Responsibilities: - Lead and deliver innovative learning programs that support the implementation and continuous improvement of DCS Growth & Enablement strategic roadmap and initiatives. - Drive the adoption of new business processes through training, communication, knowledge management, and change management. - Collaborate within Business Operations and across department leaders and functional subject-matter experts to assess training needs,

### Vice President Sales and Field Team - NSCLC - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $294K-$367K
- Posted: 2026-04-29
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7719965003
- Excerpt: Vice President Sales and Field Team - NSCLC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Oncology Sales will lead the design, build, and execution of a high-performing, national oncology sales organization supporting Revolution Medicines products/services to the oncology communityg. Reporting to the SVP of US Marketing & Sales, the VP will be responsible for creating and scaling a best-in-class sales organization, ensuring successful product launches, and driving sustained revenue growth. This leader will combine strategic vision with operational rigor, leveraging deep oncology expertise and cross-functional collaboration to position the organization for long-term success. Key Responsibilities: Organizational Build & Leadership - Architect and execute the build-out of a national oncology sales organization, including hiring, onboarding, and development of regional leaders, account directors, and sales representatives. - This will include nurse educator and other field facing roles or functions including sales operations and training. - Establish organizational structure, roles, and deployment strategy aligned to brand

### Associate Director, Accounting - Japan - Revolution Medicines
- Location: Remote (Japan) (remote)
- Salary: Not disclosed
- Posted: 2026-05-21
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7742334003
- Excerpt: Associate Director, Accounting - Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an experienced, strategic, and hands-on accounting leader to build and scale the accounting and finance operations infrastructure in Japan. Reporting directly to the Head of Finance & Operations, Japan, this newly created role will play a critical role in supporting the company's transition toward future commercial readiness and long-term growth in Japan. This position will lead core accounting operations, financial systems implementation, process design, internal controls, and statutory compliance, while partnering cross-functionally to establish a scalable and compliant finance environment capable of supporting a commercial-stage organization. The role will also serve as a key business partner across Finance, Commercial, Legal, Supply Chain, HR, and global teams to help prepare the organization for future product launches and increasing operational complexity. The ideal candidate combines strong technical accounting expertise with operational leadership, systems implementation experience, and the ability to build processes and infrastructure

### Principal Product Manager, Clinical Trials Intelligence - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7739001003
- Excerpt: Principal Product Manager, Clinical Trials Intelligence Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Product Manager, Clinical Trials Intelligence to build products that help teams plan, run, monitor, analyze, submit, and follow clinical trials with greater speed, quality, and confidence.This role will define and deliver product strategy across the clinical trial continuum, from study design and startup through trial conduct, submission readiness, and post-approval safety monitoring. You will shape Clinical Trials Intelligence capabilities on RevCore, our enterprise data and AI platform, with a clear mandate to improve trial execution, enrollment predictability, data readiness, submission readiness, inspection readiness, and safety monitoring. You will work on high-stakes products where trust, usability, traceability, and speed directly affect trial execution, regulatory readiness, and patient impact. This role focuses on product strategy, user outcomes, workflow design, adoption, and measurable impact, in partnership with clinical, regulatory, safety, medical, data, technology, quality, vendor, and system owner teams.

### Executive Director, Global Scientific Communications - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $265K-$331K
- Posted: 2026-05-11
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7731549003
- Excerpt: Executive Director, Global Scientific Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a new member of the Revolution Medicines team, the Executive Director, Global Scientific Communications will lead the development and execution of a comprehensive scientific communications strategy and team, ensuring alignment across internal and external stakeholders in preparation for the company's first commercial launch in pancreatic cancer and the progression of additional pipeline assets in NSCLC, colorectal cancer, and other solid tumors. Reporting into the SVP, Global Medical Affairs, this role will will be responsible for leading our scientific communications platforms and publication strategies and contribute to medical content supporting the organization's medical and scientific engagement efforts. Key responsibilities include: Publications Strategy & Execution - Lead the development and execution of the global publication plans, ensuring alignment with clinical and scientific objectives. - Oversee and provide strategic direction for medical writing, publication planning meetings, the submission process, and timely/high-quality scientific communications and

### Associate Director, Regulatory Systems - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $186K-$233K
- Posted: 2026-05-20
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7742279003
- Excerpt: Associate Director, Regulatory Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Business Systems will lead the strategy, governance, implementation, and optimization of Regulatory Affairs technology platforms that support global regulatory operations and submission activities. This individual will serve as the business owner for key regulatory systems and partner closely with Regulatory Affairs, Regulatory Operations, IT, Quality, Clinical, and external vendors to deliver scalable, compliant, and efficient business solutions. The ideal candidate brings deep expertise in regulatory processes, business systems management, and cross-functional collaboration within a biotechnology or pharmaceutical environment. This role will play a critical part in advancing RevMed's regulatory systems roadmap and enabling operational excellence across the regulatory organization. Key Responsibilities: - Serve as the business owner and strategic lead for Regulatory Affairs systems, including Veeva RIM, Veeva Registrations, DocuBridge, and related regulatory platforms. - Drive the long-term strategy, roadmap, and governance model for regulatory business systems aligned with

### Senior Manager, Commercial Regulatory Affairs - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $164K-$205K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695672003
- Excerpt: Senior Manager, Commercial Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Senior Manager, Commercial Regulatory Affairs to partner closely with the cross-functional teams to ensure that all promotional and medical communication strategies are compliant with applicable regulations, industry standards, and internal policies. This role will help enable successful product commercialization while upholding regulatory integrity and scientific accuracy. As part of the Regulatory Affairs function, the Senior Manager will work under supervision to provide strategic regulatory advice on advertising/promotion and medical materials to the US organization for assigned products in accordance with business goals and objectives, FDA regulations/guidances, pharma guidelines, and company policy. The position can be based at our Redwood City, CA site in a hybrid work schedule (preferred) or remote-based with quarterly and as needed travel. Required Skills, Experience and Education: - Serves as a primary or secondary regulatory advertising and promotion reviewer for assigned products on

### Senior Financial Analyst/Finance Manager - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $120K-$150K
- Posted: 2026-04-22
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7686136003
- Excerpt: Senior Financial Analyst/Finance Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Sr. Financial Analyst/Finance Manager to support our growing needs in Development and R&D Finance. The successful candidate will have experience with clinical trials, R&D accruals process, month-end close, financial reporting, SOX, and audit support. This position is based out of our headquarters in Redwood City, CA. - Reporting to the Associate Director, FP&A and will serve as a business partner to Clinical Operations and cross-functional partner to Accounting, Finance, and Procurement. - Prepare month-end clinical trial accruals, including review of CRO reports, patient costs, and site payments. - Prepare monthly and quarterly reconciliations for accrued clinical and related prepaid accounts. - Contribute to Identify, design, and implement process improvements to streamline clinical trial accruals, reducing manual effort and improving accuracy and timeliness. - Review contracts and amendments to analyze and determine impact on clinical accruals. - Prepare contract

### Director, Medical Analytics and Exploratory Data Science - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7694158003
- Excerpt: Director, Medical Analytics and Exploratory Data Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and scientifically rigorous Director of Biostatistics to our Medical Analytics and Exploratory Data Science Biostatistics group. This role will provide strategic and hands-on statistical leadership for exploratory data analyses, scientific publications, real-world evidence (RWE), post-marketing research, and health economics and outcomes research (HEOR) initiatives. The successful candidate will serve as a key statistical leader and individual contributor, partnering closely with cross-functional teams to generate high-quality evidence that advances our oncology pipeline and supports medical and scientific strategy. - Provide statistical leadership for exploratory data analyses using existing clinical trial data, real world data studies, post-marketing research, and HEOR projects. - Serve as a primary statistical contact for assigned projects, working collaboratively with clinical development, medical affairs, safety, statistical programming, regulatory affairs and commercial. - Lead the design, analysis, and interpretation of complex statistical models,

### Director, Global Medical Affairs – GI Oncology - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-05-12
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7732352003
- Excerpt: Director, Global Medical Affairs – GI Oncology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Medical Affairs will report to the GI Tumors Medical Affairs Strategy Lead and will be responsible for supporting the development and execution of the Global Medical Affairs (GMA) strategy and tactical plans for Revolution Medicines assets being developed for the treatment of GI cancers, with a focus on PDAC and CRC. Key aspects of this role include the following: support the development and execution of a Healthcare Professional (HCP) engagement strategy to gather insights that shape internal programs; act as the medical representative on cross-functional teams; serve as a therapeutic area content expert; and support medical affairs functions as needed. As a member of the GMA team, the successful candidate will participate in the Global Medical Affairs Team (GMAT) to execute medical strategies, contribute to the operations and oversight of medical activities, and work cross-functionally to support

### Director, Global Patient Safety Operations - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-05-29
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7737064003
- Excerpt: Director, Global Patient Safety Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly skilled and experienced Director of Global Patient Safety Operations to join our team. Reporting to the Head of Global Patient Safety Operations, this role provides leadership and oversight of safety operations, including management of pharmacovigilance vendors and serving as an internal subject matter expert. The Director will mentor and develop direct reports, execute the department's vision and strategy, and work collaboratively with cross-functional teams. In addition, the Director will collaborate cross-functionally to continuously develop and maintain the pharmacovigilance system to support Revolution Medicines' research, development, and marketed products. - Lead and manage direct reports of the Global Patient Safety Operations team - Oversee procedures related to Individual Case Safety Report processing, oversight of metrics, and compliance with global safety reporting requirements. - Oversee pharmacovigilance vendors and CROs, ensuring quality, budget, and timely delivery of safety operations activities.

### Senior Director, Clinical Development - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $244K-$305K
- Posted: 2026-04-30
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7721222003
- Excerpt: Senior Director, Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Director of Clinical Development in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research to pivotal studies including regulatory submissions. You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as primary point-of-contact for questions/enquires regarding the CDP at a program level, oversee the conduct of medical/safety data

### Vice President, Regulatory Affairs - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $294K-$367K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695252003
- Excerpt: Vice President, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Regulatory Affairs will manage several key U.S. based regulatory functions and report to the SVP of Regulatory and Quality. The position is responsible for expanding and leading a large, high functioning regulatory group and ensuring global alignment. - Provide ethical and mission-driven leadership of the Regulatory Affairs functions. Embody and practice the company's mission-driven culture. Ensure that our core values guide our strategic vision and our day-to-day decision making. - Provide a vision for the Regulatory Affairs organization and develop a plan to achieve it. Design and rapidly scale a group to meets the needs of an explosive pipeline in areas of high unmet medical need and intense industry competition. - Influence decision-making of senior leadership and ensure globally aligned regulatory decision-making. - Collaborate closely and form effective relationships with other functional heads and regional counterparts to ensure high quality,

### Senior Manager, Compliance - Field Commercialization (East) - Revolution Medicines
- Location: Remote (United States) (remote)
- Salary: $164K-$205K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695675003
- Excerpt: Senior Manager, Compliance - Field Commercialization (East) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Compliance - Field Commercialization is responsible for providing hands-on support to Commercial and Medical field teams during product commercialization and indication expansion. This role serves as a primary field-facing compliance partner, ensuring compliant execution of field activities while enabling business objectives. Reporting to the Senior Director, Compliance the Senior Manager will implement and continuously enhance a comprehensive field-facing compliance program, embedding compliance into daily field operations while supporting the company's growth as commercial stage oncology organization. Field Compliance Support - This role will support the Senior Director, Compliance in providing field-facing corporate compliance support for all Revolution Medicines (RevMed) field roles, including field Sales, field Marketing, Medical Science Liaisons, and field Reimbursement and Access teams. - This role will serve as primary compliance contact for questions related to field activities. - The Senior Manager will partner with Headquarter Compliance,

### Director, Biostatistics - Early Phase - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $211K-$264K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7693896003
- Excerpt: Director, Biostatistics - Early Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and studies and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle. - Provide statistical support and strategic input to clinical development plans and target product profiles, proof of concept criteria, and team's preparation for company governance reviews. - Represent Biostatistics function on cross-function teams at program level and serve as a lead statistician for oncology studies - Collaborate with various functions on study design and planning, protocol development, statistical analysis plan and analysis specifications. - Provide statistical support for study protocol development, analysis plan and specification through direct involvement and/or providing guidance to junior staff. - Plan and prepare independent data monitoring committee (DMC), coordinate with independent statistical

### Vice President, Global CMC Regulatory - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $294K-$367K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7694393003
- Excerpt: Vice President, Global CMC Regulatory Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished, strategic and execution-oriented leaders, Vice President, Global CMC Regulatory, reporting to SVP of Pharmaceutical Development and Manufacturing (PDM) Regulatory, to lead our global chemistry, manufacturing, and controls (CMC) regulatory strategy and execution across all development programs and commercial assets. This leader will drive regulatory strategy development, lead regulatory interactions, and provide expertise throughout the product lifecycle, from early development to post-approval variations ensuring the timely submission and approval of high-quality CMC regulatory filings to support our company's pipeline and global growth. The successful candidate will serve as a senior leadership role within Pharmaceutical Development and Manufacturing (PDM) organization, overseeing CMC regulatory activities and ensuring alignment with health authority expectations globally (FDA, EMA, PMDA, NMPA, etc.). The role requires expertise in small molecule pharmaceutical development and manufacturing, an understanding of the oncology development lifecycle, and the ability to

### Senior Clinical Program Manager - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $164K-$205K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695516003
- Excerpt: Senior Clinical Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Sr. Clinical Program Manager, you will be responsible for acting as a central contact for the Clinical Study Team(s) and assist with the execution and management of Revolution Medicines (RevMed) clinical trials. Responsibilities: - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed. - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. -

### Vice President, Analytical Development & Quality Control - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $294K-$367K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695261003
- Excerpt: Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline.

### Senior Director, Clinical Development - Late Phase - Revolution Medicines
- Location: Redwood City, California, United States (unspecified)
- Salary: $244K-$305K
- Posted: 2026-04-10
- 401(k) match: listed (not source-backed)
- Apply: https://www.revmed.com/careers-list/?gh_jid=7695557003
- Excerpt: Senior Director, Clinical Development - Late Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Director of Clinical Development in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research to pivotal studies including regulatory submissions. You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as primary point-of-contact for questions/enquires regarding the CDP at a program level, oversee the conduct

---
Source-backed benefit claims include source links; other benefit values are labeled separately.